The Deep-Tech Founder Using AI to Address Immunology Challenges

Why It Matters

AI‑driven translational insight can slash costly late‑stage failures, delivering effective therapies to patients faster and preserving biotech capital.

Key Takeaways

• EVA predicts therapeutic efficacy early in development.
• Multidisciplinary team bridges biology and machine learning.
• AI aims to cut immunology drug attrition rates.
• Better trial design accelerates patient access to treatments.
• Immuno‑inflammatory diseases affect 10% of Western population.

Pulse Analysis

Immuno‑inflammatory disorders affect roughly one in ten people in the West, yet drug pipelines for conditions such as rheumatoid arthritis, lupus and inflammatory bowel disease suffer from chronic inefficiencies. Late‑stage attrition rates often exceed 50%, translating into billions of dollars in sunk costs and delayed patient access. Traditional approaches rely on fragmented data and intuition, leaving critical biological signals undiscovered. In this environment, AI offers a systematic way to parse multi‑omics datasets, model disease pathways, and forecast clinical outcomes, promising a paradigm shift in how biotech firms allocate resources and prioritize candidates.

Scienta Lab’s EVA embodies this shift. Built as a multimodal transformer, EVA ingests genomic, proteomic and phenotypic data to answer three core questions: which targets merit investment, which preclinical signals are likely to translate to humans, and which patient sub‑groups will respond to a given therapy. Early‑stage predictions enable companies to abandon low‑probability programs before expensive animal studies, while later‑stage stratification refines trial enrollment, improving statistical power and reducing trial duration. By quantifying therapeutic efficacy before first‑in‑human dosing, EVA shortens the feedback loop between bench and bedside, directly addressing the attrition bottleneck that has long plagued immunology.

The broader implication extends beyond a single platform. Successful AI integration demands teams that speak both biology and code, a principle Bouget emphasizes. Companies that silo data science from domain expertise risk building models that miss critical immunological nuance. As venture capital increasingly backs deep‑tech biotech, investors are looking for firms that demonstrate this interdisciplinary rigor. If EVA’s early results hold, the model could become a template for AI‑augmented drug development across therapeutic areas, reshaping R&D economics and ultimately delivering life‑changing treatments to patients faster.